Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02610296 · ClinicalTrials.gov registry record · Phase 3
QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant
A Phase 3 study, sponsored by Quark Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 594
- Enrollment target
NCT02610296: Completed Phase 3 study, sponsored by Quark Pharmaceuticals.
NCT02610296 is a Phase 3 study that has completed, run by Quark Pharmaceuticals. The registered enrollment target is 594 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (23% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02610296, a Phase 3 study, has completed, sponsored by Quark Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 594 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate the reduction in incidence and severity of delayed graft function with kidney allografts from donors \>45 years after brain death (DBD).
Interventions
- OTHER Placebo
- DRUG QPI-1002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 594 participants |
| Start Date | 2016-03-01 |
| Est. Completion | 2019-01-08 |
| Phase | Phase 3 |
What the finished NCT02610296 record still lists
NCT02610296 is an interventional study that assigns participants to a tested intervention. The registered 594 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (23% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02610296 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02610296 about?
NCT02610296 is a clinical study titled "QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant". The purpose of this trial is to evaluate the reduction in incidence and severity of delayed graft function with kidney allografts from donors \>45 years after brain death (DBD).
What is the current status of trial NCT02610296?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 594 participants. The study started on 2016-03-01. Estimated completion is 2019-01-08.
What interventions are being tested in trial NCT02610296?
The interventions under investigation include: Placebo (OTHER), QPI-1002 (DRUG).
Who is sponsoring clinical trial NCT02610296?
This trial is sponsored by Quark Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02610296's enrollment target sits among peer trials
594 642nd of 2000 higher than 1,358 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04701684 · 594 participants · NA
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
- NCT05491213 · 594 participants · NA
TELESCOPE- TELEhealth Shared Decision-making COaching
- NCT05867420 · 594 participants · Phase 1
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
- NCT06890884 · 594 participants · Phase 2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI